CD274 and melanoma: In order to explore other potential biomarkers, a study enrolled in 18 melanoma patients was conducted to evaluate whether PD-L1 mRNA level in plasma-derived EVs could reflect response to the anti-PD-1 agents, such as nivolumab and pembrolizumab.